Cipla launches 100 mg Rectal Artesunate Suppositories for yo
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Drug major Cipla, in partnership with Medicines for Malaria Venture (MMV), has launched 100 mg Artesunate Rectocaps/Rectal Artesunate Suppositories (RAS), a life-saving, pre-referral intervention for the management of malaria in children. It contains 100 mg of Artesunate and is indicated in children from 6 months to 6 years. The drug was recently added to the Global Fund expert review panels list of quality-assured medicines, while the process of WHO pre-qualification of this medicine moves through its final stages...



http://bit.ly/2tJiQDn
Preview
Dr. A●●●●a s●●●●●s and 1 others like this2 shares
Like
Comment
Share